AstraZeneca is to work with Quell Therapeutics to develop its Treg cell therapies in two autoimmune disease areas, paying out $85m upfront in a deal which could be worth well over $2bn.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?